| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2077668 | Cell Stem Cell | 2010 | 4 Pages |
Abstract
Human stem cell biology is driving the promise of novel regenerative therapies into clinical trials. Although the pharmaceutical industry has embraced stem cells as tools in drug discovery, few companies have taken the risk to deliver stem cell-based medicines. Here, we evaluate the various cell-based opportunities and corporate strategies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Ruth McKernan, John McNeish, Devyn Smith,